Study shows proof-of-concept for nipocalimab in lupus

The neonatal Fc receptor blocker nipocalimab exhibited significant improvement over placebo in systemic lupus erythematosus at 24 and 52 weeks, according to data presented at the EULAR 2026 Congress.
“Especially in lupus, IgG antibodies can be pathogenic,” said Richard A. Furie, MD, of the division of rheumatology at Northwell Health.
Furie additionally noted that IgG antibodies “provoke inflammation,” participate in the formation of circulating immune complexes and cause cellular cytotoxicity via several different mechanisms.
“These are pathogenic antibodies that we would love to eliminate,” he

Human Metapneumovirus Is Elevated Nationally This Week — and Most Emergency Room Doctors Are Not Testing for the Respiratory Virus That Hospitalizes 200,000 Americans Every Year

CDC's Respiratory Illnesses Data Channel (June 12, 2026) confirms human metapneumovirus (HMPV) is elevated nationally. HMPV hospitalizes 200,000 Americans annually, disproportionately affects older adults and immunocompromised patients, and is routinely missed because most clinicians test only for flu and RSV.

A Fungal Pathogen That Can Destroy Vision Triggered a Clinic Outbreak Linked to Eye Procedures — A New CDC MMWR Investigation Published This Week Exposes a Critical Gap in Ophthalmic Safety

CDC MMWR (January/June 2026): Purpureocillium lilacinum keratitis was linked to an ophthalmology clinic in New York City (2024) and a pseudo-outbreak at a dermatology clinic in Washington. P. lilacinum is an antifungal-resistant mold that can cause permanent vision loss. Here is what patients and clinicians need to know.